Recurrent point mutations clustering around the ligand binding domain (LBD) of ESR1 that cause single amino acid residue changes have been found in up to 40% of treatment-refractory, metastatic ER+ breast cancer patients (reviewed in 1). This evidence concerns the gene ESR1 and breast carcinoma.